As demonstrated in Figure 3, the APIS BC Subtyping Kit correctly assigned positive status to 6 out of 7 HER2 2+ ISH positive tumors, and negative status to 57 out of 62 HER2 2+ ISH negative tumors. Here, ERBB2 is linked to breast cancer.